Clinical trials: Ambulation Disorder, Neurologic
Sensorimotor Gait Disorder, Neurologic Ambulation Disorder
Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop
The objective of this study is to determine the effectiveness of the NESS L300 (L300) in improving gait parameters, function, and quality of life among stroke subjects (greater than or equal to 3 months post stroke)with drop foot.
- Conditions
- Sensorimotor Gait Disorder, Neurologic Ambulation Disorder, Gait, Drop Foot, Poststroke Hemiparesis
- Trial name
- L300 (NCT01138995)
- Testing
- Ness L300, Ankle-foot orthosis
- Where
- 11 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bioness Inc
Spinal Cord Injuries, Paraplegia and Tetraplegia
Self-balancing Personal Exoskeleton for SCI (WIP)
This study aims to demonstrate the safety and effectiveness of the personal exoskeleton in individuals with spinal cord injury (SCI).
- Trial name
- NCT07536386
- Testing
- Hands-free exoskeleton
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Wandercraft
Spinal Cord Injuries, Tetraplegia
Human Factors Validation Testing of the Wandercraft Personal Exoskeleton
The goal of this interventional, national, prospective, open and monocentric study is to demonstrate that a personal exoskeleton can be used by the intended users without serious use errors or problems, for the intended uses and…
- Conditions
- Spinal Cord Injuries, Tetraplegia, Paraplegia
- Trial name
- ExoUser (NCT06715631)
- Testing
- Hands-free exoskeleton
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Wandercraft
Sarcopenia, Gait Disorders in Old Age
An OBServational Clinical Trial (SARA-OBS) in Sarcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over
The SARA-OBS is a single arm phase 2 clinical trial, with no investigational product and no therapeutic intervention that will be conducted in three European countries, (Belgium, France and Italy), and in the US.
- Conditions
- Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
- Trial name
- SARA-OBS (NCT03021798)
- Testing
- No Drug and no aspecific intervention
- Where
- 7 sites in United States, Belgium and 2 more
- Volunteers
- 218 people
- Sponsor
- Biophytis
Spinal Cord Injuries
Clinical Investigation on Feasibility and Usability of the ABLE Exoskeleton Device for Individuals With Spinal Cord Injury to Perform Skills for Home and Community Environments
The loss of the ability to walk and the associated restriction of mobility presents a major challenge to people with spinal cord injury in an everyday environment designed for pedestrians.
- Trial name
- NCT05643313
- Testing
- ABLE Exoskeleton
- Where
- 2 sites in Germany, Spain
- Volunteers
- 10 people
- Sponsor
- ABLE Human Motion S.L.
Osteoarthritis of Knee, Edema
Microcurrent Stimulation Reduces Post-Operative Swelling and Healing Time Following Knee Replacement Surgery
The purpose of this study is to determine if patients undergoing a total knee arthroplasty (TKA) experience a clinically significant reduction in healing time when treated post operatively with a specific form of micro and…
- Conditions
- Osteoarthritis of Knee, Edema, Wounds and Injuries
- Trial name
- NCT02623660
- Testing
- ODIN1, Standard Care, Diagnostic Device Testing
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bioelectric Research Corporation
Peripheral Neuropathy With Type 2 Diabetes, Peripheral Neuropathy Grade 2 or Greater
Wearable Sensory Prosthesis to Improve Coordination, Walking, and Physical Activity
The goal of this clinical trial is to investigate whether sensory stimulations from a neuroprosthesis device (Walkasins®) can increase physical activity and improve gait quality in persons with peripheral neuropathy (PN).
- Conditions
- Peripheral Neuropathy With Type 2 Diabetes, Peripheral Neuropathy Grade 2 or Greater, Balance, Balance Impairment, Gait Disorders, Fatigue
- Trial name
- NCT07554443
- Testing
- External, lower limb sensory prosthesis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- RxFunction Inc.
Stroke, Acute, Stroke, Ischemic
Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4)
The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial.
- Conditions
- Stroke, Acute, Stroke, Ischemic, Stroke, Subacute, Stroke Hemorrhagic
- Trial name
- EarlyExo (NCT06107010)
- Testing
- Use of the Atalante exoskeleton
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- Wandercraft
Spinal Cord Injuries, Gait Disorders, Neurologic
Safety and Feasibility of TWIICE Rise
The aim of this study is to assess the safety and the feasibility of two versions of TWIICE Rise for exoskeleton-assisted ambulation in patients with a spinal cord injury.
- Trial name
- NCT05926310
- Testing
- TWIICE Rise
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- TWIICE
Multiple Sclerosis
Patient Centered Outcomes Analysis for MS Using a Mobile Application
Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that can impact all aspects of nervous system function.
- Trial name
- NCT04281160
- Testing
- BeCare Mobile App
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BeCare Link LLC
Spinal Cord Injuries (SCI), Paraplegia and Tetraplegia
Self-balancing Personal Exoskeleton for SCI
This study aims to demonstrate the safety and effectiveness of the Eve personal exoskeleton in individuals with spinal cord injury (SCI).
- Trial name
- NCT06777576
- Testing
- Hands-free exoskeleton
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Wandercraft
Spinal Cord Injuries
Clinical Investigation on the Impact on Safety, Feasibility and Usability of the Design Changes Performed on ABLE Exoskeleton Device With Spinal Cord Injured Patients in a Hospital Setting
The loss of the ability to walk and the associated restriction of mobility presents a major challenge to people with spinal cord injury in an everyday environment designed for pedestrians.
- Trial name
- NCT05590065
- Testing
- ABLE Exoskeleton
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- ABLE Human Motion S.L.
Multiple Sclerosis
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
The purpose of the study is to show that individuals treated with Fampridine-SR tablets are significantly more likely to have consistent improvements in their walking than those treated with placebo tablets.
- Trial name
- NCT00483652
- Testing
- Fampridine-SR
- Where
- 40 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months, or until it becomes commercially available whichever comes first, in subjects who…
- Trial name
- NCT00648908
- Testing
- Fampridine-SR
- Where
- 32 sites in United States, Canada
- Volunteers
- 269 people
- Sponsor
- Acorda Therapeutics
Spinal Cord Injuries (SCI), Paraplegia and Tetraplegia
Self-balancing Personal Exoskeleton for SCI (Site 2)
This study aims to demonstrate the safety and effectiveness of the personal exoskeleton in individuals with spinal cord injury (SCI).
- Trial name
- NCT06814015
- Testing
- Hands-free exoskeleton
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Wandercraft
Multiple Sclerosis
Evaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
This clinical research study is investigating whether the EXOPULSE Suit, a wearable device that delivers electrical stimulation, can help improve movement difficulties caused by spasticity in adults with multiple sclerosis (MS).
- Trial name
- EXO-MS (NCT07897760)
- Testing
- Electrostimulation suit
- Where
- 2 sites in United States, Germany
- Volunteers
- 100 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Parkinson's Disease (PD)
The Influence of Vibrotactile Stimulation on Self-selected Walking Speed in People With Parkinson's Disease
The study tests whether a smart shoe (NUSHU) that provides vibrotactile stimulation can improve walking speed in people with Parkinson's disease.
- Trial name
- NCT07308418
- Testing
- Vibrotactile feedback during walking
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Magnes AG
Adrenomyeloneuropathy, Adrenoleukodystrophy
MD1003-AMN MD1003 in Adrenomyeloneuropathy
The primary objective of the trial is to demonstrate the superiority of biotin at 300 mg/day over placebo in the clinical improvement (walking tests) of patients with adrenomyeloneuropathy
- Conditions
- Adrenomyeloneuropathy, Adrenoleukodystrophy, AMN
- Trial name
- NCT02961803
- Testing
- MD1003 100 mg capsule
- Where
- 4 sites in France, Germany and 1 more
- Volunteers
- 67 people
- Sponsor
- MedDay Pharmaceuticals SA
Spinal Cord Injuries
Clinical Investigation on Safety, Feasibility and Usability of the ABLE Exoskeleton Device With Spinal Cord Injured Patients in a Hospital Setting
The loss of the ability to walk and the associated restriction of mobility presents a major challenge to people with spinal cord injury in an everyday environment designed for pedestrians.
- Trial name
- NCT04876794
- Testing
- ABLE Exoskeleton
- Where
- 2 sites in Germany, Spain
- Volunteers
- 24 people
- Sponsor
- ABLE Human Motion S.L.
Walking Impairment, Multiple Sclerosis
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.
- Trial name
- NCT03436199
- Testing
- ADS-5102, 137 mg, ADS-5102, 274 mg
- Where
- 84 sites in United States, Canada
- Volunteers
- 558 people
- Sponsor
- Adamas Pharmaceuticals, Inc.